KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accounts Payables: 2020-2025

Historic Accounts Payables for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $53.1 million.

  • AbCellera Biologics' Accounts Payables fell 1.22% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $55.0 million for FY2024, which is 10.94% up from last year.
  • AbCellera Biologics' Accounts Payables amounted to $53.1 million in Q3 2025, which was up 6.08% from $50.1 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Accounts Payables peaked at $55.0 million during Q4 2024, and registered a low of $13.3 million during Q1 2021.
  • For the 3-year period, AbCellera Biologics' Accounts Payables averaged around $46.9 million, with its median value being $49.6 million (2023).
  • As far as peak fluctuations go, AbCellera Biologics' Accounts Payables surged by 114.82% in 2023, and later declined by 16.11% in 2024.
  • AbCellera Biologics' Accounts Payables (Quarterly) stood at $32.0 million in 2021, then soared by 63.97% to $52.5 million in 2022, then decreased by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024, then decreased by 1.22% to $53.1 million in 2025.
  • Its Accounts Payables stands at $53.1 million for Q3 2025, versus $50.1 million for Q2 2025 and $47.8 million for Q1 2025.